Department of Gastroenterology, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.
Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.
J Formos Med Assoc. 2021 Feb;120(2):794-803. doi: 10.1016/j.jfma.2020.08.019. Epub 2020 Aug 26.
Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis, as the last stage of numerous chronic liver diseases, is one of the most relevant prognostic factors. The liver biopsy with the histopathological examination is considered to be the "gold standard" for the identification and staging of the hepatic fibrosis. However, liver biopsy is known as an invasive investigation that has multiple limitations. Research studies conducted in the last few years focused on identifying non-invasive type methods for the evaluation of hepatic fibrosis; usually, there are 2 categories of such investigations: serologic tests and imaging techniques. This narrative review presents the non-invasive investigation methods used in the liver fibrosis evaluation. New molecular perspectives on fibrogenesis and fibrosis regression, as well as the appearance of therapeutic antifibrotic agents, justify the necessity of non-invasive tools to detect and grade liver fibrosis.
全球每年约有 200 万人死于肝脏疾病。肝纤维化是许多慢性肝病的终末期阶段，是最重要的预后因素之一。肝活检结合组织病理学检查被认为是识别和分期肝纤维化的“金标准”。然而，肝活检是一种有创性的检查，存在多种局限性。近年来的研究集中在寻找非侵入性方法来评估肝纤维化；通常，有两种类型的研究：血清学检测和影像学技术。本综述介绍了用于评估肝纤维化的非侵入性检查方法。纤维化发生和纤维化消退的新分子观点，以及治疗性抗纤维化药物的出现，证明了需要非侵入性工具来检测和分级肝纤维化。
